Wire · opportunities
AI Superforecasting Should Transform The FDA
◆ Sectors
Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The article proposes integrating AI-driven superforecasting into the FDA's clinical trial and drug approval processes to reduce subjectivity and delays by providing quantitative predictions on outcomes and risks.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You need to prepare for AI tools directly influencing FDA decisions and clinical trial design. Expect drug development to focus on meeting new quantitative benchmarks rather than appeasing subjective reviewer preferences.
◆ Coverage
1 source · 16 Sep 2026
◆ Related on Wire
◆ Topics
HealthAI-forecastingFDA-reformclinical-trialsdrug-approvalregulatory-process